Kasper Søltoft Larsen1, Anton Pottegård2, Hanne M Lindegaard3, Jesper Hallas4. 1. Department of Clinical Chemistry & Pharmacology, Odense University Hospital, Odense C, Denmark; Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense C, Denmark; Department of Rheumatology, Odense University Hospital, Odense C, Denmark. Electronic address: kaslarsen@health.sdu.dk. 2. Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense C, Denmark. 3. Department of Rheumatology, Odense University Hospital, Odense C, Denmark. 4. Department of Clinical Chemistry & Pharmacology, Odense University Hospital, Odense C, Denmark; Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense C, Denmark.
Abstract
BACKGROUND: Hyperuricemia and gout have been associated with increased cardiovascular risk. Allopurinol is an effective urate-lowering drug. Whether lowering of urate by allopurinol improves the cardiovascular risk in hyperuricemic patients remains to be established. OBJECTIVE: Our objective was to investigate the effect of allopurinol on cardiovascular outcomes in hyperuricemic patients in an observational setting. METHODS: We had access to a study population consisting of all patients from Funen County, Denmark with high urate levels (≥6 mg/dL) from 1992 to 2010. We linked 4 registries; all blood samples, all in- and outpatient contacts in hospitals, all reimbursed prescriptions and causes of death. We identified all incident allopurinol users and matched them 1:1 to nonusers of urate-lowering therapy, with similar urate levels, by using propensity scores. Hazard ratios were calculated using competing risk regression model, with respect to Antiplatelet Trialists' Collaboration composite outcome (myocardial infarction, stroke, or cardiovascular death) and all-cause mortality. RESULTS: Among 65,971 patients with hyperuricemia, we found 7127 patients on allopurinol treatment. In the propensity score-matched cohort we found a hazard ratio of 0.89 (95% confidence interval, 0.81-0.97) for the main outcome among allopurinol treated compared with nonusers of allopurinol. The corresponding hazard ratio for all-cause mortality was 0.68 (95% confidence interval, 0.62-0.74). CONCLUSION: Allopurinol treatment is associated with a decreased cardiovascular risk among hyperuricemic patients.
BACKGROUND:Hyperuricemia and gout have been associated with increased cardiovascular risk. Allopurinol is an effective urate-lowering drug. Whether lowering of urate by allopurinol improves the cardiovascular risk in hyperuricemicpatients remains to be established. OBJECTIVE: Our objective was to investigate the effect of allopurinol on cardiovascular outcomes in hyperuricemicpatients in an observational setting. METHODS: We had access to a study population consisting of all patients from Funen County, Denmark with high urate levels (≥6 mg/dL) from 1992 to 2010. We linked 4 registries; all blood samples, all in- and outpatient contacts in hospitals, all reimbursed prescriptions and causes of death. We identified all incident allopurinol users and matched them 1:1 to nonusers of urate-lowering therapy, with similar urate levels, by using propensity scores. Hazard ratios were calculated using competing risk regression model, with respect to Antiplatelet Trialists' Collaboration composite outcome (myocardial infarction, stroke, or cardiovascular death) and all-cause mortality. RESULTS: Among 65,971 patients with hyperuricemia, we found 7127 patients on allopurinol treatment. In the propensity score-matched cohort we found a hazard ratio of 0.89 (95% confidence interval, 0.81-0.97) for the main outcome among allopurinol treated compared with nonusers of allopurinol. The corresponding hazard ratio for all-cause mortality was 0.68 (95% confidence interval, 0.62-0.74). CONCLUSION:Allopurinol treatment is associated with a decreased cardiovascular risk among hyperuricemicpatients.
Authors: Seoyoung C Kim; Tuhina Neogi; Eun Ha Kang; Jun Liu; Rishi J Desai; MaryAnn Zhang; Daniel H Solomon Journal: J Am Coll Cardiol Date: 2018-03-06 Impact factor: 24.094
Authors: Megha Prasad; Eric L Matteson; Joerg Herrmann; Rajiv Gulati; Charanjit S Rihal; Lilach O Lerman; Amir Lerman Journal: Hypertension Date: 2016-12-19 Impact factor: 10.190
Authors: Isla S Mackenzie; Ian Ford; Andrew Walker; Chris Hawkey; Alan Begg; Anthony Avery; Jaspal Taggar; Li Wei; Allan D Struthers; Thomas M MacDonald Journal: BMJ Open Date: 2016-09-08 Impact factor: 2.692